Status:
ENROLLING_BY_INVITATION
Tryptophan-Kynurenine Pathway Metabolism in the Pathophysiology of Cognitive Impairment in Schizophrenia.
Lead Sponsor:
Tianjin Anding Hospital
Conditions:
Schizophrenia
Eligibility:
All Genders
18-55 years
Brief Summary
Schizophrenia is a common, long-term mental illness. It causes problems with thoughts, feelings, and behavior, including positive symptoms (hallucinations, delusions), negative symptoms (lack of emoti...
Detailed Description
This single-center, prospective study will recruit 100 treatment-naïve, first-episode schizophrenia (SZ) patients at Tianjin Anding Hospital for an 8-week follow-up. All patients will receive monother...
Eligibility Criteria
Inclusion
- Healthy volunteers matched to the patient group on sex, age, and education level;
- Ethnic Han Chinese;
- Able and willing to provide written informed consent.
Exclusion
- Significant comorbid medical or neurological conditions;
- Any DSM-5-defined psychiatric disorder;
- Family history of psychiatric illness spanning three or more generations;
- Current use of psychoactive medications;
- Refusal to provide informed consent/participate.
Key Trial Info
Start Date :
February 19 2024
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
June 30 2026
Estimated Enrollment :
200 Patients enrolled
Trial Details
Trial ID
NCT07162467
Start Date
February 19 2024
End Date
June 30 2026
Last Update
September 9 2025
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Tianjin Anding Hospital
Tianjin, China